spacer
home > ict
PUBLICATIONS

International Clinical Trials

 
International Clinical Trials (ICT) is a specialist journal designed to provide global coverage of key topics pertinent to the clinical trials sector.

Published quarterly, and edited by Dr Graham Hughes, the journal offers a platform of communication and information-sharing for executive and strategic decision-makers, seeking out new trends and marketing opportunities, as well as putting a spotlight on the latest innovations coming to market. ICT is specifically designed to be of interest to those actively seeking to source services for improved efficiency in what is an increasingly competitive market.

 
For further information please contact:

Advertising
Nick Matthews   

Editorial
Rupert Gilbey

Connect with us on Twitter: follow @IntClinTrials

Read our publications on the go in the Samedan app for iPhone and iPad. You can download issues for offline reading and our archives go as far back as 2008! Download for free on the App Store.


View the digital version of ICT

ict
 
 
Featured in this issue
Regional Trials
Biosimilars

Like Minded


Europe has led the charge in bringing biosimilars to market and, despite the difficulties in developing these therapeutic proteins, pharma companies are not put off. Casting a regional eye at Central and Eastern Europe, Magdalena Matusiak and Anna Baran from KCR explain the development route.
Data Management & Statistical Analysis
Statistical Analysis

Data Driven


When it comes to statistical programming, pharma companies are leaning towards an offshoring strategy to help realise cost advantages and more accurate analysis of trial data. Chitra Lele from Sciformix gives some tips on how to optimise and sustain a globally distributed model.
  Regional Trials
Market Analysis: Russia

Federal Factors


Russia has been a rising star of clinical R&D for 20 years, but the slowdown in market growth and emerging competition might block further progress. Maria Bomer at Bomer Pharma Consultancy assesses the country's trial landscape and the mixed success of new regulation.

spacer
Edited by
Dr Graham Hughes
Consultant in
Pharmaceutical
Development

Published quarterly in
February, May,
August and November

Banner of Adallen.ICT on Samedan
Banner of Europital.ICT on Samedan
 
Industry Events

Exploratory Clinical Development World Europe

2-3 June 2015, Bishopsgate, London, UK

Exploratory Clinical Development World Europe is recognised as the premier conference for understanding the right strategies and methods to assess safety & efficacy and make timely go/no go decisions.
More info >>

 
News and Press Releases

Three Innovations to Protect Laboratories, Products and Patients

At PharmaPack Europe on February 11-­‐12, 2015, Advanced Track & Trace® introduced its latest innovations in terms of authentication, traceability and patient relationship management.
More info >>

air transport logo

 

White Papers

Phase II trial of Trigemina’s TI-001 for high frequency migraine

Exco InTouch Ltd

Trigemina’s TI-001 is a patented application of a formulation including oxytocin with a novel mode of action (MOA) as a therapy for high frequency migraine. Open label data suggests that TI-001 holds the promise to be safe and effective in reducing moderate and severe headache day frequency among this population by more than 50%, with corresponding decreases in secondary migraine symptoms (nausea, vomiting etc.) and use of acute medications, a significant improvement compared to current drugs.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement